InspireMD, a cutting-edge medical device company focusing on innovative stent designs and neurovascular protection systems, has successfully raised $17.9 million in funding. The company's unique MicroNet™ technology is revolutionizing the industry standard for treating carotid artery disease, providing exceptional acute results and long-term stroke prevention through their proprietary stent platform, CGuard™ EPS. With a mission to reduce stroke occurrences during and after carotid artery stenting procedures, InspireMD is poised to lead the market in advancing stroke prevention technologies. The funding will enable the company to further develop and enhance their groundbreaking products, solidifying their position as a key player in the field of medical device innovation. InspireMD's presence on NASDAQ Capital Markets (NSPR) showcases their commitment to growth and success in delivering advanced solutions for stroke prevention and neurovascular protection.
Breaking News: InspireMD Secures $17.9M in Funding for Innovative Stent Technology Revolutionizing Stroke Prevention
Recently funded · $17.9MHealthcare
Get the full InspireMD company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
